Constipation - Pipeline Review, H2 2016 - Global Markets Direct - Market Research

Constipation - Pipeline Review, H2 2016

Constipation - Pipeline Review, H2 2016 - Global Markets Direct - Market Research
Constipation - Pipeline Review, H2 2016
Published Jul 20, 2016
121 pages — Published Jul 20, 2016
Price US$ 2,000.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Constipation - Pipeline Review, H2 2016, provides an overview of the Constipation pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Constipation, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Constipation and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Constipation
- The report reviews pipeline therapeutics for Constipation by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Constipation therapeutics and enlists all their major and minor projects
- The report assesses Constipation therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Constipation

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Constipation
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Constipation pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing

  
Source:
Document ID
GMDHC8299IDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents26
  List of Tables61
  List of Figures71
Introduction81
  Global Markets Direct Report Coverage81
Constipation Overview91
Therapeutics Development102
  Pipeline Products for Constipation Overview101
  Pipeline Products for Constipation Comparative Analysis111
Constipation Therapeutics under Development by Companies122
Constipation Therapeutics under Investigation by Universities/Institutes141
Constipation Pipeline Products Glance153
  Late Stage Products151
  Clinical Stage Products161
  Early Stage Products171
Constipation Products under Development by Companies182
Constipation Products under Investigation by Universities/Institutes201
Constipation Companies Involved in Therapeutics Development2120
  AlbireoPharma211
  Ardelyx, Inc.221
  Astellas Pharma Inc.231
  Braintree Laboratories, Inc.241
  CJ HealthCare Corp.251
  EA Pharma Co Ltd261
  Ironwood Pharmaceuticals, Inc.271
  Kissei Pharmaceutical Co., Ltd.281
  Motus Therapeutics Inc291
  NGM Biopharmaceuticals, Inc.301
  RaQualia Pharma Inc.311
  Sanwa Kagaku Kenkyusho Co., Ltd.321
  Shire Plc331
  SK Biopharmaceuticals Co., Ltd.341
  Sucampo Pharmaceuticals, Inc.351
  Sumitomo Dainippon Pharma Co., Ltd.361
  Synergy Pharmaceuticals, Inc.371
  Synthetic Biologics, Inc.381
  Torrent Pharmaceuticals Limited391
  Yuhan Corporation401
Constipation Therapeutics Assessment419
  Assessment by Monotherapy Products411
  Assessment by Target422
  Assessment by Mechanism of Action442
  Assessment by Route of Administration462
  Assessment by Molecule Type482
Drug Profiles5057
  5-BIOP Drug Profile501
  AJG-555 Drug Profile511
  ASP-7663 Drug Profile521
  BLI-400 Drug Profile531
  BLI-801 Drug Profile541
  CJ-14199 Drug Profile551
  DA-6886 Drug Profile561
  DSP-6952 Drug Profile571
  elobixibat Drug Profile582
  KWA-0711 Drug Profile601
  linaclotide Drug Profile617
  lovastatin Drug Profile683
  lubiprostone Drug Profile718
  NGM-282 Drug Profile792
  plecanatide Drug Profile817
  prucalopride succinate Drug Profile882
  prucalopride succinate Drug Profile901
  relamorelin Drug Profile915
  relenopride hydrochloride Drug Profile961
  RQ-00000010 Drug Profile972
  SK-1202 Drug Profile991
  tenapanor hydrochloride Drug Profile1005
  Transilon Drug Profile1051
  YH-12852 Drug Profile1061
Constipation Dormant Projects1071
Constipation Product Development Milestones10812
  Featured News &Press Releases1081
    Jun 09, 2016: Ironwood and Allergan Announce Supplemental New Drug Application for 72 mcg Linaclotide in Chronic Idiopathic Constipation Has Been Accepted for FDA Review1081
    May 24, 2016: Synergy Pharmaceuticals Presents New In Vitro Data Showing the pH-Dependent Activity of Plecanatide Replicates That of Naturally Occurring GI Peptide Uroguanylin1081
    May 23, 2016: Synthetic Biologics Announces Detailed Data from Two SYN-010 Phase 2 Clinical Trials for the Treatment of Irritable Bowel Syndrome with Constipation (IBS-C)1082
    May 22, 2016: Synergy Pharmaceuticals Presents New Plecanatide Phase 3 Data in Chronic Idiopathic Constipation at Digestive Disease Week1101
    May 21, 2016: Synergy Pharmaceuticals Presents Additional Phase 3 Plecanatide Data in Chronic Idiopathic Constipation at Digestive Disease Week1102
    May 17, 2016: Ironwood Pharmaceuticals to Present Linaclotide Data at Digestive Disease Week 20161121
    May 17, 2016: Synthetic Biologics to Host Post-DDW 2016 Conference Call to Recap SYN-010 Phase 2 Clinical Trial Results for the Treatment of Irritable Bowel Syndrome with Constipation (IBS-C)1131
    May 16, 2016: Synergy Pharmaceuticals to Present New Plecanatide Data at Digestive Disease Week 20161131
    May 11, 2016: Isaac J. Bright, MD, Joins Synthetic Biologics as Vice President, Corporate Development1141
    Apr 19, 2016: Synergy Pharmaceuticals Announces Acceptance of New Drug Application for Plecanatide, a Novel Uroguanylin Analog, in Chronic Idiopathic Constipation1151
    Feb 29, 2016: Video Alert: Updated 2016 Direct-to-Consumer Awareness Campaign Available for LINZESS (linaclotide)1151
    Feb 17, 2016: Synthetic Biologics Announces the Allowance of Key U.S. Patent Covering SYN-010 intended for the Novel Treatment of Irritable Bowel Syndrome with Constipation1151
    Jan 29, 2016: Synergy Pharmaceuticals Files New Drug Application for Plecanatide in Chronic Idiopathic Constipation1161
    Jan 19, 2016: Synthetic Biologics Reports Positive Topline Data from Second Phase 2 Clinical Trial of SYN-010 in Patients with Irritable Bowel Syndrome with Constipation (IBS-C)1171
    Dec 08, 2015: Synthetic Biologics' SYN-010 Lowered Breath Methane and Improved Stool Frequency in a Phase 2 Four Week Study in Patients with Irritable Bowel Syndrome with Constipation (IBS-C)1182
Appendix1202
  Methodology1201
  Coverage1201
  Secondary Research1201
  Primary Research1201
  Expert Panel Validation1201
  Contact Us1201
  Disclaimer1211

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Constipation - Pipeline Review, H2 2016" Jul 20, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Constipation-Pipeline-Review-H2-2016-2088-16262>
  
APA:
Global Markets Direct - Market Research. (2016). Constipation - Pipeline Review, H2 2016 Jul 20, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Constipation-Pipeline-Review-H2-2016-2088-16262>
  
US$ 2,000.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.